Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M47,117Revenue (TTM) $M19,552Net Margin (%)7.6Altman Z-Score1.9
Enterprise Value $M56,544EPS (TTM) $1.5Operating Margin %10.5Piotroski F-Score6
P/E(ttm)34.4Beneish M-Score-2.8Pre-tax Margin (%)11.8Higher ROA y-yN
Price/Book1.810-y EBITDA Growth Rate %11.2Quick Ratio1.0Cash flow > EarningsY
Price/Sales2.45-y EBITDA Growth Rate %2.5Current Ratio1.3Lower Leverage y-yY
Price/Free Cash Flow10.7y-y EBITDA Growth Rate %40.3ROA % (ttm)2.8Higher Current Ratio y-yY
Dividend Yield %2.6PEG13.8ROE % (ttm)4.9Less Shares Outstanding y-yN
Payout Ratio %91.0Shares Outstanding M914ROIC % (ttm)2.6Gross Margin Increase y-yY

Gurus Latest Trades with TEVA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
TEVAJulian Robertson 2016-06-30 Sold Out -4.78%$48.53 - $57.25
($53.24)
$ 51.55-3%Sold Out0
TEVAJohn Paulson 2016-06-30 Reduce-1.55%$48.53 - $57.25
($53.24)
$ 51.55-3%Reduce -18.58%16,773,800
TEVABarrow, Hanley, Mewhinney & Strauss 2016-06-30 Add1.03%$48.53 - $57.25
($53.24)
$ 51.55-3%Add 143.69%22,700,812
TEVAFirst Eagle Investment 2016-06-30 Reduce-0.26%$48.53 - $57.25
($53.24)
$ 51.55-3%Reduce -99.99%200
TEVANWQ Managers 2016-06-30 Reduce-0.24%$48.53 - $57.25
($53.24)
$ 51.55-3%Reduce -14.45%1,677,841
TEVAKeeley Asset Management Corp 2016-06-30 Add0.03%$48.53 - $57.25
($53.24)
$ 51.55-3%Add 32.85%58,169
TEVARonald Muhlenkamp 2016-06-30 Reduce-0.01%$48.53 - $57.25
($53.24)
$ 51.55-3%Reduce -0.29%176,655
TEVADavid Dreman 2016-06-30 Reduce$48.53 - $57.25
($53.24)
$ 51.55-3%Reduce -2.09%33,274
TEVAJulian Robertson 2016-03-31 Reduce-2.02%$53.5 - $65.86
($58.8)
$ 51.55-12%Reduce -40.16%356,200
TEVANWQ Managers 2016-03-31 Add0.49%$53.5 - $65.86
($58.8)
$ 51.55-12%Add 42.10%1,961,208
TEVAFirst Eagle Investment 2016-03-31 Reduce-0.4%$53.5 - $65.86
($58.8)
$ 51.55-12%Reduce -56.18%1,915,660
TEVADavid Dreman 2016-03-31 Buy 0.21%$53.5 - $65.86
($58.8)
$ 51.55-12%New holding33,983
TEVAJohn Paulson 2016-03-31 Add0.08%$53.5 - $65.86
($58.8)
$ 51.55-12%Add 0.95%20,602,200
TEVAVanguard Health Care Fund 2016-03-31 Add0.07%$53.5 - $65.86
($58.8)
$ 51.55-12%Add 9.60%6,356,700
TEVABarrow, Hanley, Mewhinney & Strauss 2016-03-31 Reduce-0.03%$53.5 - $65.86
($58.8)
$ 51.55-12%Reduce -2.99%9,315,460
TEVAKeeley Asset Management Corp 2016-03-31 Add0.02%$53.5 - $65.86
($58.8)
$ 51.55-12%Add 20.34%43,784
TEVARonald Muhlenkamp 2016-03-31 Add$53.5 - $65.86
($58.8)
$ 51.55-12%Add 0.12%177,160
TEVAJulian Robertson 2015-12-31 Buy 5.04%$55.96 - $66.32
($61.94)
$ 51.55-17%New holding595,300
TEVAJohn Paulson 2015-12-31 Add0.97%$55.96 - $66.32
($61.94)
$ 51.55-17%Add 13.39%20,409,300
TEVANWQ Managers 2015-12-31 Reduce-0.89%$55.96 - $66.32
($61.94)
$ 51.55-17%Reduce -42.70%1,380,143
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

TEVA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


TEVA: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about TEVA:

    News about TEVA:

    Articles On GuruFocus.com
    Allergan: An Undervalued Powerhouse Aug 28 2016 
    A Comprehensive Look at Dividend Growth Stock Valuations Sector by Sector: Part 2 Aug 26 2016 
    Swiss Generics Manufacturer Has Strong 1st Half of Year Aug 22 2016 
    Allergan Narrowly Beats Earnings, Thanks to Sales Surge Aug 09 2016 
    Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 
    Andreas Halvorsen Buys Facebook, Amazon, MasterCard Jun 14 2016 
    Growing Generic Drug Market a Good Opportuity for 2 India Firms May 30 2016 
    Stocks Near 52-Week Lows May 26 2016 
    John Keeley Comments on Teva Pharmaceuticals Apr 26 2016 
    Pfizer-Allergen Merger Deal End Hurts Some Funds But Helps Many Apr 08 2016 

    More From Other Websites
    Billionaire John Paulson’s Favorite Healthcare Stocks Include The Latest Industry Punching Bag,... Aug 27 2016
    FTC spells out new concerns over generic drug mergers Aug 26 2016
    FTC Details Concerns on Generic Drug Company Mergers Aug 26 2016
    After Mylan uproar, a generic EpiPen could hit the market in 2017 Aug 26 2016
    Mylan Reacts to EpiPen Backlash Aug 26 2016
    Mylan's EpiPen Price Increases Highlight Its Grip on the Market Aug 26 2016
    US Patent and Trademark Office Invalidates Two Copaxone 40 Patents Aug 25 2016
    Specialty Pharma: Never Mind the Pricing Controversy, Fundamentals Will Win Out Aug 25 2016
    Why is there no generic EpiPen? Aug 25 2016
    Teva Stock Gains, Leerink: Despite Patent Loss, No Generic Competition Until 2018 Aug 25 2016
    Will Teva Pharmaceutical Strengthen Specialty Pipeline in 3Q16? Aug 25 2016
    Top Analyst Upgrades and Downgrades: DDR, HP, L-3 Communications, Salesforce.com, Teva, Twilio and... Aug 25 2016
    Major Pharma Short Interest Faces Significant Drop Aug 25 2016
    Mylan (MYL) Obtains Favorable USPTO Ruling for Copaxone Aug 25 2016
    Mylan wins round in fight with Teva over multiple sclerosis drug Aug 24 2016
    Shares of Teva Pharmaceuticals fall after US Patent Office invalidates two patents Aug 24 2016
    Teva Confirms PTAB’s Decisions on Two Patents in IPR Challenge to COPAXONE® 40 mg Aug 24 2016
    What's next for Mylan? Aug 24 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)